

Joint press release from the City of Dessau and IDT Biologika

IDT Biologika acquires former Schade Brewery site from city of Dessau

Modern training and conference center planned for downtown Dessau

Dessau-Rosslau, Germany, January 22, 2016. IDT Biologika and Klocke Holding have purchased the former Schade Brewery from the city of Dessau. A new training and conference center will be built on the site for use by both IDT Biologika and other entities. The property acquisition was handled through two project management companies and finalized on December 23, 2015. Details of the deal remain confidential.

For years, what was once the privately owned Schade Brewery on Lange Gasse remained shuttered, waiting to be repurposed and hampering urban planning efforts to create an attractive downtown. In 2015 the city of Dessau was able to purchase the centrally located property, and has now signed an agreement with IDT Biologika and Klocke Holding under which the brewery's architecturally significant components will be renovated and integrated into a modern training and conference center. The new design will establish the Schade Brewery site as an anchor for revitalizing the downtown area.

"This construction project affirms IDT Biologika's commitment to doing business in our city," says Dessau Mayor Peter Kuras. "Moreover, it is clear that the decision to locate the future Bauhaus Museum here has sparked a cycle of improvements consistent with our vision for downtown." The city council approved the sale of the site on December 9.



"The new conference and training center satisfies the needs of our dynamic, growing company for a conference facility to welcome customers and business partners from around the world," says Dr. Ralf Pfirmann, CEO of IDT Biologika. "We also need adequate space to train and educate our growing team so that they can continue to develop the most modern vaccines and biological agents for global health care in the 21st century. This building will give IDT Biologika a prominent location in downtown Dessau. IDT and Klocke Holding affirm their responsibility for the development of the region. These steps represent a deliberate effort to enhance Dessau's downtown."

Andreas Kastenbauer, Managing Director of IDT Biologika, gave an overview of the project: "Building will start immediately after an extensive planning phase now in progress. A modern training and conference center will be built during the first construction phase with the aim of helping to revitalize Dessau's downtown and add to the uses of the convention center. That's why project plans include construction of facilities that are necessary for the whole building complex."

The Schade Brewery site is located in the Dessau-Rosslau district close to downtown. The brewery was founded in 1833. The brewing facility in Lange Gasse was built in 1898 but suffered severe damage in 1945. Following the war, the brewery was incorporated into the state-owned VEB Brewery Dessau, which closed in 1990 after an eventful few decades of operation. Since then, the building and grounds have mostly stood unused. The city of Dessau bought the property in 2015 and resold it to IDT Biologika and Klocke Holding at the end of the year, also forming a joint project to redesign the site.

About IDT Biologika

IDT Biologika is an innovative, privately-held company with more than 95 years of experience in researching, developing, manufacturing and marketing products for human and animal health. Established in 1921, IDT Biologika has become one of



the world's leading pharmaceutical and biotechnological companies, producing vaccines and pharmaceuticals according to the highest national and international quality standards. The company's sites in Germany include the BioPharmaPark in Dessau-Rosslau and the Riems district of Greifswald. IDT operates subsidiaries in Denmark, the Netherlands, France and Spain, which focus on the company's Animal Health business segment. In June 2015, IDT Corporation opened a manufacturing site for clinical trials in Rockville, Maryland.

In 2015, IDT Biologika drew on its animal health, vaccines, parenteral products, biological agents and drug packaging divisions to achieve revenues of approximately EUR 202 million, a 17 percent increase over the previous year. IDT Biologika currently employs around 1,500 individuals.

IDT Biologika is a member of the Klocke Group. Klocke Holding companies specialize in contract manufacturing and packaging medications, vaccines and cosmetic products. A traditional family-owned company, the Klocke Holding Group employs a workforce of more than 2,100 in Europe and the United States. The group offers comprehensive services for the manufacture and packaging of pharmaceutical products in eight locations.

Contact:

Peter Kellner Tel. +49-34901-885-5681 Mobile +49-162-4248453 peter.kellner@idt-biologika.de

IDT Biologika GmbH Am Pharmapark, 06861 Dessau-Rosslau, Deutschland